Table 5.
Baseline Characteristics of Low-Risk Group Under 3-Monthly and 6-Monthly Surveillance from Year 1 after Treatment
| Variable | Original set | Matched set | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| 3-Monthly surveillance (n=376) | 6-Monthly surveillance (n=314) | p-value* | 3-Monthly surveillance (n=140) | 6-Monthly surveillance (n=140) | p-value* | |
| Age, yr | 57 (51–62) | 56 (50–63) | 0.34 | 56 (50–62) | 56 (51–63) | 0.72 |
| Male sex | 306 (81.4) | 219 (69.8) | <0.001 | 100 (71.4) | 95 (67.9) | 0.60 |
| Etiology | 0.59 | 0.21 | ||||
| HBV | 309 (82.2) | 251 (79.9) | 120 (85.7) | 108 (77.2) | ||
| HCV | 17 (4.5) | 11 (3.5) | 7 (5.0) | 7 (5.0) | ||
| HBV+HCV | 7 (1.9) | 6 (1.9) | 2 (1.4) | 3 (2.1) | ||
| Others† | 43 (11.4) | 46 (14.7) | 11 (7.9) | 22 (15.7) | ||
| CTP score | 5 (5–5) | 5 (5–5) | 0.71 | 5 (5–5) | 5 (5–5) | 0.81 |
| MELD score | 8 (7–9) | 8 (7–9) | 0.39 | 8 (7–9) | 8 (7–8) | 0.19 |
| AST, U/L | 34 (26–43) | 32 (25–44) | 0.26 | 35 (27–44) | 31 (36–43) | 0.19 |
| ALT, U/L | 35 (24–51) | 33 (22–49) | 0.28 | 35 (25–53) | 32 (23–51) | 0.27 |
| Albumin, g/dL | 4.1 (3.9–4.4) | 4.1 (3.9–4.4) | 0.66 | 4.2 (3.9–4.4) | 4.1 (3.9–4.3) | 0.22 |
| Total bilirubin, mg/dL | 0.9 (0.7–1.1) | 0.9 (0.7–1.1) | 0.51 | 0.9 (0.8–1.1) | 0.9 (0.7–1.1) | 0.14 |
| Creatinine, mg/dL | 0.9 (0.8–1.1) | 0.9 (0.8–1.1) | 0.82 | 1.0 (0.8–1.1) | 0.9 (0.8–1.1) | 0.29 |
| PT INR | 1.1 (1.0–1.1) | 1.1 (1.0–1.1) | 0.40 | 1.1 (1.0–1.1) | 1.1 (1.0–1.1) | 0.40 |
| Platelet, ×103/μL | 142 (108–177) | 148 (108–183) | 0.41 | 132 (109–172) | 151 (110–184) | 0.08 |
| AFP, ng/mL | 8.9 (4.2–52.4) | 10.0 (4.5–117.0) | 0.30 | 8.9 (4.2–80.6) | 10.8 (4.8–102.0) | 0.44 |
| Tumor size, cm | 2.3 (1.7–3.0) | 2.3 (1.6–3.4) | 0.18 | 2.3 (1.6–3.0) | 2.2 (1.7–3.0) | 0.51 |
| No. of tumor | 0.35 | 1.00 | ||||
| 1 | 330 (87.8) | 286 (91.1) | 125 (89.3) | 126 (90.0) | ||
| 2 | 38 (10.1) | 24 (7.6) | 13 (9.3) | 12 (8.6) | ||
| 3 | 8 (2.1) | 4 (1.3) | 2 (1.4) | 2 (1.4) | ||
| BCLC stage | 0.92 | 0.39 | ||||
| 0 | 140 (37.2) | 119 (37.9) | 52 (37.1) | 60 (42.9) | ||
| A | 236 (62.8) | 195 (62.1) | 88 (62.9) | 80 (57.1) | ||
| Treatment method | 0.02 | 0.55 | ||||
| RFA | 226 (60.1) | 160 (51.0) | 84 (60.0) | 78 (55.7) | ||
| Resection | 150 (39.9) | 154 (49.0) | 56 (40.0) | 62 (44.3) | ||
Data are presented as median (interquartile range) or number (%).
HBV, hepatitis B virus; HCV, hepatitis C virus; CTP, Child-Turcotte-Pugh; MELD, Model for End-Stage Liver Disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT INR, international normalized ratio for prothrombin time; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; RFA, radiofrequency ablation.
*
p-value estimated by chi-square test or Fisher exact test for categorical variables and Mann-Whitney U test;
†
Other causes included alcohol, non-alcoholic fatty liver disease, primary biliary cholangitis, and autoimmune hepatitis.